Patients and methods: We retrospectively evaluated the results in patients diagnosed with high risk leukemias or MDS of our MAC-HAPLO regimens (Fludarabine 30 mg/m2 x5 days (-6 to -2), Cyclophosphamide14,5 mg/kg x2 days (-6 to -5), IV Busulfan 3,2 mg/kg x 3 days (BUX3) on days -4 to -2, or Fludarabine 40 mg/m2 x4 days (-6 to -2) and IV Busulfan 3,2 mg/kg x 4 days (BUX4)) with GVHD prophylaxis based on PT-CY (50 mg/kg on days +3 and +4) and a calcineurin inhibitor plus mycophenolate from day +5, performed in GETH centers.
Results: From Feb-2011, 24 MAC-HAPLO have been done in 7 centers. Median age was 37 years (15-65), 58% were males and all were in advanced disease phase or presented high risk features (AML 16/ALL 4/MDS 2/ CML-BC 1/ CMML 1). Previous HSCT had been employed in 21% (autologous in 1, allogeneic in 4), and in 79% the HAPLO-HSCT was their first transplant. Disease status at HAPLO-HSCT was morphologic CR in 83%, but with persistent disease (morphologic or MRD+ by flow or molecular markers) in 67%. BM was the graft source in 3 patients (12.5%) and PBSC in 21 (87.5%), non T-cell depleted in all cases. The haploidentical donor was the patient´s mother (21%), father (12.5%), siblings (41.5%) or offspring (25%). MAC regimen was BUX3 in 8 (33%) and BUX4 in 16 patients (67%). Median infused CD34+ cells were 4,93x10e6/kg (3,20-8,43). Median neutrophils engraftment was reached at day +16 (13-29) and platelets >20K at day +27 (11-131). Complete chimerism was obtained at a median of 22 days (13-44) in 21 evaluated patients. Cumulative incidence (CI) of non-relapse mortality (NRM) was 21.5% at 1 year. CI of grade II-IV acute GVHD was 45.5% at day +100, and grade III-IV was 9%. CI of chronic GVHD at 1 year was 35%, being extensive in 8% . No differences in acute or chronic GvHD CI were seen when comparing BUX3 against BUX4. After a median follow-up of 15 months (3-31), estimated 18-months event-free survival (EFS) and overall survival (OS) were 63% and 75% respectively. CI of relapse or progression was 19.5%. No significant differences in NRM, EFS, OS and relapse incidence were detected between BUX3 and BUX4. The effect of CR prior to MAC-HAPLO has not been apropiately assesed due to the limited number of events in our series.
Conclusions: IV Busulfan based MAC-HAPLO with PT-CY in the treatment of high risk leukemias and MDS offers good disease control with manageable toxicity, with either BUX3 or BUX4.